Equities research analysts expect that Illumina, Inc. (NASDAQ:ILMN) will report earnings per share of $1.34 for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for Illumina’s earnings, with estimates ranging from $1.30 to $1.39. Illumina posted earnings per share of $1.45 during the same quarter last year, which indicates a negative year-over-year growth rate of 7.6%. The business is scheduled to issue its next quarterly earnings report on Tuesday, April 23rd.

On average, analysts expect that Illumina will report full-year earnings of $6.53 per share for the current fiscal year, with EPS estimates ranging from $6.42 to $6.56. For the next financial year, analysts anticipate that the firm will post earnings of $7.50 per share, with EPS estimates ranging from $7.27 to $7.70. Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Illumina.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, January 29th. The life sciences company reported $1.32 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.04). The business had revenue of $867.00 million during the quarter, compared to the consensus estimate of $865.33 million. Illumina had a return on equity of 24.51% and a net margin of 24.79%. The firm’s revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.44 earnings per share.

Several research analysts recently issued reports on ILMN shares. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $339.00 price target for the company in a research note on Friday, February 22nd. Bank of America reiterated a “buy” rating and issued a $355.00 price target on shares of Illumina in a research note on Wednesday, January 30th. UBS Group upgraded shares of Illumina from a “neutral” rating to a “buy” rating and increased their price target for the stock from $340.00 to $370.00 in a research note on Thursday, January 3rd. Morgan Stanley decreased their price target on shares of Illumina from $320.00 to $288.00 and set an “equal weight” rating for the company in a research note on Monday, January 7th. Finally, Deutsche Bank lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $296.53 price target for the company. in a research note on Friday, January 25th. Five equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $345.82.

In other Illumina news, Director Karin Eastham sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, January 2nd. The shares were sold at an average price of $294.08, for a total transaction of $1,470,400.00. Following the completion of the sale, the director now directly owns 12,655 shares in the company, valued at approximately $3,721,582.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Charles Dadswell sold 124 shares of the firm’s stock in a transaction dated Wednesday, January 2nd. The shares were sold at an average price of $294.71, for a total transaction of $36,544.04. Following the sale, the senior vice president now owns 7,003 shares of the company’s stock, valued at $2,063,854.13. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,226 shares of company stock valued at $9,597,270. 0.54% of the stock is owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the business. Machina Capital S.A.S. bought a new stake in Illumina during the 4th quarter valued at about $1,099,000. Occidental Asset Management LLC grew its stake in shares of Illumina by 7.8% in the fourth quarter. Occidental Asset Management LLC now owns 690 shares of the life sciences company’s stock worth $207,000 after acquiring an additional 50 shares during the period. Norges Bank bought a new stake in shares of Illumina in the fourth quarter worth approximately $514,627,000. Actinver Wealth Management Inc. bought a new stake in shares of Illumina in the fourth quarter worth approximately $279,000. Finally, Financial Advocates Investment Management grew its stake in shares of Illumina by 1,430.0% in the fourth quarter. Financial Advocates Investment Management now owns 612 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 572 shares during the period. Institutional investors and hedge funds own 90.37% of the company’s stock.

Shares of Illumina stock opened at $305.14 on Tuesday. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.49 and a quick ratio of 2.27. The stock has a market capitalization of $44.38 billion, a P/E ratio of 52.81, a price-to-earnings-growth ratio of 2.15 and a beta of 1.18. Illumina has a 1 year low of $225.82 and a 1 year high of $372.61.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Featured Article: Hedge Funds – How They Work For Investors

Get a free copy of the Zacks research report on Illumina (ILMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.